Rituximab-Induced Severe Acute Thrombocytopenia: A case Report and Review of Literature
Rituximab-Induced Severe Acute Thrombocytopenia: A case Report and Review of Literature
复制标题
DOI：
10.1080/07357900802010509
复制
发表时间：
2008-01-01
影响因子：
2.4
通讯作者：
Bahrain, Huzefa
中科院分区：
文献类型：
--
作者：
Dhand, Suneel;Bahrain, Huzefa
利妥昔单抗是一种抗CD20单克隆抗体，通常是一种安全且耐受性良好的药物。利妥昔单抗给药后发生严重急性血小板减少症是一种罕见的现象，文献中以前报道的病例很少。我们报告一例84岁男性诊断为套细胞淋巴瘤谁遭受严重的急性血小板减少后利妥昔单抗输注。文献回顾以前发表的情况下也提出。
Rituximab, an anti-CD20 monoclonal antibody, is generally a safe and well-tolerated drug. Severe acute thrombocytopenia following administration of rituximab is a rare phenomenon, with few previously reported cases in the literature. We report a case of an 84-year old male with a diagnosis of mantle cell lymphoma who suffered severe acute thrombocytopenia following rituximab infusion. A literature review of the previously published cases is also presented.